Funding for this research was provided by:
First Online: 22 April 2020
Compliance with Ethical Standards
: This work was supported by Shionogi & Co., Ltd., Osaka, Japan.
: Kazuya Fukumura, Nao Kawaguchi, Toru Ishibashi, Ryuji Kubota, Yukio Tada, and Eriko Ogura are employees of Shionogi & Co, Ltd.
: The data used in this manuscript are confidential and not accessible to the public.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (IntegReview [P-gp inhibitor study], IRB#00003657; Chesapeake IRB [CYP3A inducer study], IRB#00000790; Medical Corporation Heishinkai OPHAC [CYP3A inhibitor study], Hospital IRB) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual study participants included in the study.